Susquehanna International Group
LGND icon

Susquehanna International Group’s Ligand Pharmaceuticals LGND Stock Holding History

Susquehanna International Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
6,703
+1,294
+24% +$256K ﹤0.01% 7170
2025
Q4 		$1.02M Sell
5,409
-3,398
-39% -$653K ﹤0.01% 7142
2025
Q3 		$1.56M Sell
8,807
-20,253
-70% -$3.01M ﹤0.01% 6320
2025
Q2 		$3.3M Buy
29,060
+6,295
+28% +$673K ﹤0.01% 4774
2025
Q1 		$2.39M Buy
22,765
+15,151
+199% +$1.71M ﹤0.01% 5138
2024
Q4 		$816K Sell
7,614
-9,778
-56% -$1.11M ﹤0.01% 7468
2024
Q3 		$1.74M Buy
17,392
+5,393
+45% +$543K ﹤0.01% 5557
2024
Q2 		$1.01M Sell
11,999
-3,015
-20% -$240K ﹤0.01% 6568
2024
Q1 		$1.1M Sell
15,014
-262
-2% -$19.3K ﹤0.01% 6665
2023
Q4 		$1.09M Buy
15,276
+4,032
+36% +$238K ﹤0.01% 6785
2023
Q3 		$674K Buy
11,244
+4,357
+63% +$287K ﹤0.01% 7537
2023
Q2 		$497K Sell
6,887
-221
-3% -$16.6K ﹤0.01% 8332
2023
Q1 		$523K Sell
7,108
-5,711
-45% -$406K ﹤0.01% 8449
2022
Q4 		$856K Sell
12,819
-12,387
-49% -$805K ﹤0.01% 6527
2022
Q3 		$1.35M Buy
+25,206
New +$1.48M ﹤0.01% 5852
2022
Q2 		– Sell
-20,009
Closed -$1.14M – 13488
2022
Q1 		$1.4M Sell
20,009
-2,306
-10% -$167K ﹤0.01% 6307
2021
Q4 		$2.15M Buy
22,315
+3,233
+17% +$299K ﹤0.01% 5339
2021
Q3 		$1.66M Sell
19,082
-54,013
-74% -$4.18M ﹤0.01% 6242
2021
Q2 		$5.98M Buy
73,095
+69,721
+2,066% +$5.8M ﹤0.01% 3696
2021
Q1 		$321K Sell
3,374
-86,146
-96% -$8.14M ﹤0.01% 10461
2020
Q4 		$5.55M Buy
89,520
+83,321
+1,344% +$4.75M ﹤0.01% 3255
2020
Q3 		$369K Sell
6,199
-800
-11% -$54.6K ﹤0.01% 8298
2020
Q2 		$489K Sell
6,999
-16,376
-70% -$1.04M ﹤0.01% 7417
2020
Q1 		$1.06M Buy
23,375
+12,715
+119% +$721K ﹤0.01% 5275
2019
Q4 		$694K Sell
10,660
-23,668
-69% -$1.58M ﹤0.01% 6285
2019
Q3 		$2.13M Sell
34,328
-133,282
-80% -$8.37M ﹤0.01% 4054
2019
Q2 		$11.9M Buy
167,610
+154,092
+1,140% +$11.3M ﹤0.01% 1722
2019
Q1 		$1.06M Buy
+13,518
New +$1.02M ﹤0.01% 4923
2018
Q4 		– Sell
-6,423
Closed -$685K – 9508
2018
Q3 		$1.1M Sell
6,423
-97,721
-94% -$14.7M ﹤0.01% 5041
2018
Q2 		$13.5M Buy
104,144
+38,674
+59% +$4.32M ﹤0.01% 1650
2018
Q1 		$6.75M Buy
+65,470
New +$6.47M ﹤0.01% 2176
2017
Q1 		– Sell
-66,315
Closed -$4.36M – 9489
2016
Q4 		$4.2M Buy
+66,315
New +$4.18M ﹤0.01% 2706
2016
Q1 		– Sell
-8,122
Closed -$494K – 9383
2015
Q4 		$549K Sell
8,122
-13,860
-63% -$856K ﹤0.01% 6573
2015
Q3 		$1.18M Sell
21,982
-28,509
-56% -$1.73M ﹤0.01% 5370
2015
Q2 		$3.18M Buy
50,491
+35,556
+238% +$1.94M ﹤0.01% 3742
2015
Q1 		$718K Buy
14,935
+1,428
+11% +$54.7K ﹤0.01% 6406
2014
Q4 		$448K Sell
13,507
-6,426
-32% -$209K ﹤0.01% 7429
2014
Q3 		$584K Sell
19,933
-21,530
-52% -$715K ﹤0.01% 6931
2014
Q2 		$1.61M Buy
41,463
+25,295
+156% +$1.03M ﹤0.01% 5074
2014
Q1 		$679K Sell
16,168
-165
-1% -$6.88K ﹤0.01% 6208
2013
Q4 		$536K Buy
+16,333
New +$532K ﹤0.01% 6578
2013
Q3 		– Sell
-11,819
Closed -$333K – 8601
2013
Q2 		$276K Buy
+11,819
New +$213K ﹤0.01% 6937

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Susquehanna International Group's LGND Position: Q1 2026 in Review

Susquehanna International Group increased its Ligand Pharmaceuticals (LGND) stake by 24% in Q1 2026, buying an estimated $256K and bringing the position to 6,703 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #7170.

Susquehanna International Group first reported a position in LGND in Q2 2013 and has held it in 42 quarters since. The position peaked at $13.5M in Q2 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Susquehanna International Group held 6,703 shares of Ligand Pharmaceuticals worth $1.34M as of Q1 2026.
  • Susquehanna International Group bought 1,294 Ligand Pharmaceuticals shares in Q1 2026, an estimated $256K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7170 holding.
  • Susquehanna International Group first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Susquehanna International Group's Ligand Pharmaceuticals position peaked at $13.5M in Q2 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.